Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
In-vitro Colorectal Cancer Screening Tests Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for in-vitro colorectal cancer screening diagnostics has experienced robust expansion lately, with projections indicating a substantial increase from $1.3 billion in 2025 to $1.4 billion in 2026, reflecting a compound annual growth rate of 7.7%. This historical growth trajectory is largely attributable to a confluence of factors, including the rising prevalence of colorectal cancer, the widening reach of public screening initiatives, a heightened societal emphasis on early cancer identification, the established availability of diagnostic laboratory facilities, and advancements in pinpointing relevant biomarkers.
The market for in-vitro colorectal cancer screening tests is poised for substantial expansion in the upcoming years, projecting a valuation of $1.82 billion by 2030 with a compound annual growth rate (CAGR) of 6.8%. This projected growth is primarily fueled by the increasing embrace of individualized screening methodologies, a burgeoning demand for convenient diagnostic options available in the home setting, the proactive expansion of preventive healthcare programs, the escalating utilization of artificial intelligence in interpreting test results, and a heightened emphasis on cost-efficient cancer detection strategies. Key developments anticipated during this forecast period involve a greater adoption of non-invasive screening methodologies, increased deployment of stool DNA tests capable of detecting multiple targets, enhanced integration of blood-based biomarker assays, broader availability of home-based sample collection kits, and a more concentrated effort on early detection within populations that exhibit no symptoms.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27319&type=smp
In-vitro Colorectal Cancer Screening Tests Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing incidence of colorectal cancer is anticipated to be a significant catalyst for the expansion of the in vitro colorectal cancer screening tests market in the future. Colorectal cancer, which originates in the colon or rectum and frequently develops from precancerous growths called polyps, is becoming more common. This surge in prevalence can be attributed to modern lifestyle choices, including inadequate dietary habits, insufficient physical activity, and obesity, all of which elevate the likelihood of polyp development and subsequent cancer. Inertestin vitro screening solutions contribute to the identification of colorectal cancer by providing less invasive techniques for the early detection of the disease. These tests enhance the precision of screening through sophisticated biomarker identification, thereby facilitating prompt treatment and improving patient prognoses. For example, in February 2025, the American Cancer Society, a non-profit organization based in the United States, reported an estimated 154,270 new cases of colorectal cancer, marking an increase from the 152,810 cases recorded in 2024. Consequently, the escalating rate of colorectal cancer is a primary driver behind the growth trajectory of the in vitro market for its screening tests.
In-vitro Colorectal Cancer Screening Tests Market Segments: Where Are The Largest Growth Opportunities?
The in-vitro colorectal cancer screening tests market covered in this report is segmented –
1) By Test Type: Fecal Occult Blood Test, Stool Deoxyribonucleic Acid Test, Blood Biomarker Test, Other Test Types
2) By Imaging Type: In-vitro Confirmatory Diagnostics, Laboratory-Based Molecular Testing, Companion Diagnostic Testing, Genetic And Epigenetic Testing, Biomarker Validation Testing, Risk Stratification Assays
3) By Application: Screening, Diagnosis, Monitoring, Risk Assessment, Post-Treatment Surveillance
4) By End User: Hospitals, Diagnostic Laboratories, Outpatient Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Fecal Occult Blood Test: Guaiac Based Fecal Occult Blood Test, Immunochemical Fecal Occult Blood Test
2) By Stool Deoxyribonucleic Acid Test: Single Target Stool Deoxyribonucleic Acid Test, Multi Target Stool Deoxyribonucleic Acid Test
3) By Blood Biomarker Test: Methylated Septin 9 Deoxyribonucleic Acid Test, Circulating Tumor Deoxyribonucleic Acid Test, Protein Biomarker Based Blood Test
4) By Other Test Types: Urine Based Biomarker Test, Serum Based Biomarker Test, Breath Based Volatile Organic Compound Test
In-vitro Colorectal Cancer Screening Tests Market Trends: What Is Shaping Future Industry Growth?
Key players within the in vitro colorectal cancer screening tests sector are prioritizing the creation of sophisticated diagnostic technologies, exemplified by multi-target stool DNA tests. The primary objectives behind this innovation are to elevate the precision of early detection, augment user-friendliness for patients, and ultimately decrease mortality rates linked to colorectal cancer. Multi-target stool DNA tests represent pioneering screening instruments designed to scrutinize stool specimens for genetic and biochemical indicators pertinent to colorectal cancer and its precursor lesions. As an illustration, in March 2025, Exact Sciences Corp., an American enterprise specializing in molecular diagnostics, introduced Cologuard Plus, an improved at-home screening test for colorectal cancer. This particular test is intended for individuals at average risk who are 45 years of age and above, and it leverages cutting-edge biomarker technology to achieve superior sensitivity and specificity when contrasted with its earlier iteration. Employing a more sophisticated algorithm, Cologuard Plus identifies both DNA alterations and hemoglobin biomarkers, thereby refining the detection capabilities for colorectal cancer and advanced adenomas alike. The Cologuard Plus test offers a screening method that is both non-invasive and user-friendly, obviating the necessity for bowel cleansing or adherence to dietary limitations, consequently fostering greater compliance among patients with established screening recommendations.
In-vitro Colorectal Cancer Screening Tests Market Major Participants And Competitive Dynamics
Major companies operating in the in-vitro colorectal cancer screening tests market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Quest Diagnostics Incorporated, Roche Diagnostics International AG, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Natera Inc., BGI Genomics Co. Ltd., NeoGenomics Inc., Guardant Health Inc., CellMax Life Inc., Epigenomics AG, Acuamark Diagnostics Inc., Beacon Biomedical Inc., Mainz Biomed NV, Hologic Inc., Danaher Corporation, Agilent Technologies Inc.
Access The Complete In-vitro Colorectal Cancer Screening Tests Market Report:
In-vitro Colorectal Cancer Screening Tests Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the in-vitro colorectal cancer screening tests market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the in-vitro colorectal cancer screening tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model